Several microbes have been suspected as pathogenetic factors in schizophrenia. We have previously observed increased frequencies of chlamydial infections and of human lymphocyte antigen (HLA)-A10 in independent studies of schizophrenia. Our aim here was to analyze frequencies of three types of Chlamydiaceae in schizophrenic patients (n = 72), random controls (n = 225) and hospital-patient controls (n = 36), together with HLA-A genotypes. Patients were diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders-IV. Blood samples were collected at the beginning of hospitalization and analyzed with Chlamydiaceae species-specific polymerase chain reaction (PCR). Control panels consisted of randomly selected volunteers and hospitalized, non-schizophrenic patients. We found chlamydial infection in 40.3% of the schizophrenic patients compared to 6.7% in the controls. The association of schizophrenia with Chlamydiaceae infections was highly significant (P = 1.39 Â 10 À10 , odds ratio (OR) = 9.43), especially with Chlamydophila psittaci (P = 2.81 Â 10
Introduction
Schizophrenia is known in all cultures and socioeconomic groups. The heterogeneity of schizophrenia remains an obstacle for investigation of causative factors. A solid cornerstone was the discovery of the genetic disposition to environmental factors (for reviews, see Karlsson, 1 Torrey and Yolken, 2 and Brown et al. ). Linkage, cytogenetic and association studies, as well as adoption and family studies, revealed the genetic predisposition of this disease. 4 Because of the incomplete concordance in identical twins, the involvement of environmental factors has been supposed and many microbial pathogens were under suspicion (for reviews, see Karlsson, 1 Torrey and Yolken, 2 and Brown et al. ). Different viruses have been the focus of several investigations, yielding significant disease associations. 1, 5, 6 We reported recently the detection of unusual antibody titers against bacterial antigens and subsequently confirmed by polymerase chain reaction (PCR) a significantly increased incidence of Chlamydiaceae infections in a small group of patients with psychiatric disorders. 7, 8 Chlamydia and Chlamydophila species are a unique class of bacteria, closely related to each other but only distantly related to other eubacteria (reviewed in ). In their biphasic life cycle, the obligate intracellular parasites can retract into a resting phase and hide their presence from the immune system for many years, although they preferably infect monocyte/macrophage populations. The family of Chlamydiaceae consists of nine species, three of which have been associated with human diseases: Chlamydia (C.) trachomatis, Chlamydophila (C.) pneumoniae and Chlamydophila (C.) psittaci.
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C. trachomatis causes oculogenital diseases, C. pneumoniae causes bronchitis pneumonia, probably coronary artery disease, 10 and might also be involved in sudden psychotic episodes. 11 C. psittaci represents the most heterogeneous group. It has been supposed to cause pneumonia, endocarditis, abortions and also a series of neurologic disorders, like meningitis, 12 cranial nerve palsy including sensory hearing loss, 13 encephalitis, 14 confusion, 14 seizures, 13 and other transient focal neurologic signs. 15 Not all individuals suffer from the same disease symptoms and to the same extent after being infected with Chlamydiaceae species. Success or failure of the individual immune response is controlled by polymorphic genes of the human lymphocyte antigen (HLA) system. We found recently that carriers of several HLA genotypes, particularly of HLA-A10, had a moderately increased risk (OR = 3.07) to develop schizophrenia. Therefore, we determined here the frequency of Chlamydiaceae infections in patients with schizophrenia. In parallel, we tested for an increased frequency of Chlamydiaceae infections in HLA-A10 schizophrenic patients.
Materials and methods

Characterization of patients and control panels
Patients with schizophrenia (n = 72) and other mental diseases (n = 36) were clinically diagnosed (Structured Clinical Interview), according to the 'Diagnostic and Statistical Manual of Mental Disorders' (DSM-IV), by two independent psychiatrists at the Psychiatric Hospital of the University of Munich (Table 1) . Subtype diagnoses of schizophrenic patients and other mental disorders are given in Table 1 . Blood samples from all patients, with or without schizophrenia, were collected at the beginning of hospitalization. Samples from the first (n = 115) and second (n = 110) random control panels (Table 2) consisted of volunteer blood donors from the institute and students. Samples from the first random panel had similar sociodemographic characteristics (male/female ratio = 0.67, age 30.078.9 years) as the patients (male/female ratio = 0.50, age 32.76710.38 years); the second control panel was built from younger volunteers (male/female ratio = 0.67, age 24.673.5 years). The non-schizophrenic patients panel was slightly older (male/female ratio = 0.41, age 43.4714.4 years, see Supplementary Table 1 ). All groups consisted of persons from the Munich area with Caucasian background. Symptoms suggesting acute Chlamydiaceae infections were not apparent in control or patient groups.
Patients gave informed consent to use the obtained information for publication, in accordance with the Collection of blood samples and DNA preparation To avoid source contamination, blood samples were collected under sterile conditions using closed vacutainer tubes (S-Monovette EDTA, Sarstedt, Germany) by the attending physicians in the hospital or by general practitioners (control group). The samples were directly transported to the laboratory and processed immediately. The peripheral blood mononuclear cells (PBMC) were divided into two portions, one was frozen and stored in liquid nitrogen, the other portion was used for immediate DNA preparation. Genomic DNA of 1 Â 10 6 PBMC of control individuals and patients was obtained by the Proteinase K method. 16 
Nested PCR
We followed the PCR method of Madico et al. 17 designed to detect less then 1 inclusion forming unit (IFU) of C. psittaci, C. pneumoniae, and C. trachomatis. 17 Each of the three oligonucleotide primer pairs is specific for C. trachomatis (CTR70/CTR71), C. pneumoniae (CPN90/CPN91) and C. psittaci (CPS100/CPS101), respectively: CTR 70, 5 0 GGC GTA TTT GGG CAT CCG AGT AAC G 111 bp with primer set CPS 100/101. To increase sensitivity, we used a preceding PCR step with a single primer set specific for all three species, based on the DNA sequences of the 16S rRNA and 16S-23S spacer rRNA genes as described: 7 Chla-Multiplex fw 5 0 ACT TGG GAA TAA CGG TTG GAA AC 3 0 , ChlaMultiplex rev 5 0 GCC TGT CAA TGC CAA GGC ATC 3 0 . In brief: in a 50 ml PCR reaction mixture, 1.0 mg of DNA, 200 mM of each dNTP (Pharmacia, Freiburg, Germany), 25 pmol of each primer, 3 mM MgCl 2 , 1 Â PCR-Puffer (Invitrogen, Karlsruhe, Germany), and 2.5 ml ELONGASE DNA polymerase (Invitrogen, Karlsruhe, Germany) were used. Cycling times were 2 min at 941C, followed by 40 cycles of denaturation at 941C for 45 s, annealing at 571C for 45 s, and extension at 681C for 90 s. A final extension step of 10 min at 681C was added. In all, 1 ml of this PCR reaction was used for the specific PCR reaction of Madico et al. 17 and followed by the published analysis. (For example, see Supplementary Figure 1 .) DNA samples were extracted and stored before the establishment of the specific PCR and use of Chlamydiaceae-specific DNA, thereby excluding contamination. All laboratory procedures were conducted in a safety hood with filtered air flow to prevent contamination. To avoid product carryover, PCRs were set up in an area physically separate from all activities involving amplified target sequences, including thermal cycling, PCR product storage, and the running of gels. A separate set of pipettes was devoted to the setup of PCRs, and aerosol barrier pipette tips were used. In addition, several interspersed negative controls were included in each experiment. A low concentration of DNA (from 10 IFU of Chlamydiaceae per PCR) was used as a positive control and was included in every PCR run.
At the beginning of the study, the researcher was blinded to patient status (schizophrenic or nonschizophrenic). To confirm results after the first PCR analysis, PCR was repeated at least once. If there was sufficient material, fresh DNA was isolated from the frozen cells and used for the second PCR. All samples were verified as positive by the second PCR. To obtain PCR amplification for sequencing, individual rather than multiplex PCRs were used. To exclude false negatives due to insufficient DNA, all samples were tested with a PCR specific for the human LMP7 gene 18 and gave positive results. To exclude inhibitory effects, all sample DNAs that gave negative results for Chlamydiaceae were tested in a separate PCR inoculated with C. trachomatis DNA and gave positive results.
Sequence analysis of PCR products
Amplification products were commercially sequenced to verify the specificity of the PCR products (Sequiserve, Munich, Germany). The primers used for cycle sequencing were CPS101, CPN91 and CTR71. 17 The sequenced genes were 16S rRNA for C. trachomatis and C. pneumoniae, and 16S and 16S-23S spacer rRNA for C. psittaci. All sequences matched the expected PCR amplification products for each organism, as verified by BLASTn search (http:// www.ncbi.nlm.nih.gov). The sequences of C. pneumoniae and C. psittaci were completely identical to published sequences; the sequence of C. trachomatis differed in only one patient by one of 290 base pairs from the published sequences, assigning it clearly to C. trachomatis.
Serological HLA types
We analyzed the correlation between Chlamydiaceae species infections and HLA-A types in schizophrenic Infected with patients whose HLA types were already reported. 19 We present here only the analysis between the significant schizophrenia-associated HLA-A10 genotype and infection with Chlamydiaceae species. , confidence intervals (CI) and odds ratio (OR). The P-values are two-tailed at a 95% significance level, with one degree of freedom for all tests.
Statistical analysis
Results
Infections with Chlamydiacea Detection of Chlamydia/Chlamydophila-specific DNA in the PBMC of 72 patients and 225 control individuals was performed by PCR analysis. The control donors were derived from two panels: the first control panel (n = 115) and the patient panel were comparable in sex and age matching. 7 The second control panel (n = 110) consisted of persons who were younger than the patients but showed a similar frequency of infections (prevalence of detectable DNA) as the first control panel (Table 2 ). Therefore, both control panels were combined (n = 225). To rule out the possibility of a bias due to a non-hospitalized control panel, we also analyzed a group of hospitalized patients suffering from other mental diseases (diagnoses are given in Table 2 and Supplementary  Table 1) , whose blood was also taken in the psychiatric hospital. This panel differed only slightly, but not significantly, from the full control panel, arguing against bias.
The three pairs of oligonucleotide primers, designed by Madico et al. 17 and used in this study, were specific for C. psittaci, C. pneumoniae and C. trachomatis, respectively. PCR products were sequenced to verify specificity in 27 of 29 samples of schizophrenic patients and 13 of 15 control samples. All sequences were compared by BLASTn search (http://www.ncbi.nlm.nih.gov) and confirmed the identity of the expected organisms.
The number of infected individuals was six times higher in the schizophrenic patient panel (40.3%) compared to the control group (6.7%), leading to a nine-fold increased odds ratio (OR = 9.43, P = 1.39 Â 10 À10 ) ( Table 3 ). The most common pathogen in single-infected patients with schizophrenia was C. psittaci, identified in 13 of 29 Chlamydiaceaeinfected patients, whereas only two of 15 Chlamydiaceae-infected controls were infected solely with C. psittaci ( Table 3 ). Calculation of the relative risk for an infection with C. psittaci alone or in combination with other chlamydial infections revealed a 21-fold increased risk of schizophrenia. Infections with other Chlamydiaceae, which were also significantly more common in schizophrenic patients than in control individuals (P = 1.59 Â 10
À3
) resulted in a lower OR of 3.91 (Table 3) . C. pneumoniae, the second most frequent single infection in schizophrenia patients, was found in 15.3% (11/72) of the patients, but in only 3.6% of the control individuals (8/225). The frequency of C. pneumoniae in controls was in agreement with frequencies found in other PCR-based investigations. 20, 21 Other investigators using the same species-specific detection method with PBMC-derived DNA, failed to detected C. psittaci in smaller control panels of 38 healthy individuals. 22 The importance of simultaneous infections with two C. species will be discussed later, particularly with regard to the blood-brain barrier. 23 Association of infections and HLA-A10 Elaboration of cytokines and specific neurotrophins during an immune response is controlled by the HLA system. We found recently an increased susceptibility to schizophrenia associated with HLA-A10 genotypes in two independent groups of patients. 19 To investigate whether HLA-A10 carriers were more prone for chlamydial infections, we compared the number of infected HLA-A10 carriers in patients and controls in the panels presented here. Only one of 25 HLA-A10-positive control individuals was infected (4%), but eight of 12 HLA-A10-positive patients were infected with Chlamydiaceae (66.7%) (Table 4, Figure 1) . The association between schizophrenia and chlamydial infection in HLA-A10 carriers culminated in an OR of 50.00 (P = 8.03 Â 10 À5 ) (Table 3) . Again, C. psittaci was the most frequent infectious agent in the HLA-A10-positive patients: six of eight (75.0%) Chlamydiaceaeinfected patients were single-or double-infected with C. psittaci (Table 4) .
We were still able to identify a significant increase in infections in HLA-A10-negative patients versus control individuals, albeit to a lesser extent (Table 5) .
Medication status and hospitalization
To exclude the possibility that the increased number of infected schizophrenic patients compared to the uninfected patients could be due to repeated hospitalization, we compared the number of hospitalizations in both groups and failed to find significant differences. In the group of infected schizophrenic patients, 19 of 29 individuals were hospitalized for the first time, compared to 20 of 43 non-infected schizophrenic patients and 23 of 36 non-schizophrenic patients. Therefore, there was no bias towards hospitalization. Most patients (80.5%) stopped disease-specific medication at least three weeks before hospitalization, indicating that medication status did not affect the results. Furthermore, none of the patients received treatment with antibiotics that would counteract chlamydial infections.
It should be noted that some neuroleptica, for example haloperidol and pimozide, have been shown in vitro to reduce infectivity of C. trachomatis in HeLa cells. 24 The concentrations used in the in vitro experiments exceeded the therapeutic dosages several fold (five-fold for haloperidol and three-fold for pimozide). Additionally, only four of our patients were pre-treated with haloperidol and one patient with pimozide. 
Discussion
Our study showed a surprisingly high number of schizophrenic patients (40.3%) infected with Chlamydiaceae species as compared to control individuals (6.7%). Infections, defined as detectable amounts of DNA, were diagnosed by PCR in mononuclear cells of the peripheral blood, which is the most sensitive method and the current gold standard for chlamydial infection recognition. 25, 26 In line with others, we did not find any significant association of the mainly sexually transmitted C. trachomatis with schizophrenia, 6 but we found a dramatically increased number of patients infected with C. psittaci. Serological assays are not adequate due to several limitations; for example, there is high cross-reactivity among Chlamydiaceae species themselves and with other organisms 27 and it is difficult to distinguish between a chronic infection and a former exposure to the pathogen(s). The Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada) regard neither elevated immunoglobulin (Ig)A titers nor any other serologic marker as validated indicators of persisting infection with C. pneumoniae. 25 Nevertheless, if IgG and IgA titers are clearly positive, they provide information that a chlamydial infection had occurred, and that the patient was able to mount an antibody response against Chlamydiaceae. In future studies, serological analysis of hospitalized patients may serve as a useful tool for attending psychiatrists and provide additional information on the role of Chlamydiaceae species in the target disease, particularly in the case of C. psittaci.
Our findings do not prove that Chlamydiaceae are causative for the schizophrenic disorder or that they affect severity or disease duration. This must be investigated in larger studies. Three results of our study, however, do support such a contention. First, C. psittaci infection, associated with the highest risk to succumb to schizophrenia (OR = 24.39), has been recognized as a neurotropic pathogen, causing several neurologic disorders, including cerebral palsy with sensory hearing loss, 13 seizures 13 and confusion.
14 Such symptoms may be due to meningitis 12 or encephalitis.
14 Second, schizophrenic patients are more frequently infected with two Chlamydophila species: C. psittaci and C. pneumoniae. C. pneumoniae has been reported to stimulate transendothelial entry of monocytes through human brain endothelial cells 23 and all three Chlamydiaceae species multiply in monocytes. The findings of Wilke et al. 28 of an increased number of monocytes in the blood of schizophrenic persons also support our assumptions. Furthermore, a recently published article of Xavier et al.
11 suggested an association of meningoencephalitis, combined with psychotic episodes, and a C. pneumoniae infection. Third, the coincidence of the highest infectious risk factor C. psittaci with the HLA-A10 genotype may be related to the documented impact of biological family relationships in the pathogenesis of schizophrenia. 19 Whether other microbial factors are involved in the pathogenesis of schizophrenia in those patients in whom we could not identify chlamydial infections remains to be determined. The PCR technique we used has high specificity but may have missed some chlamydial infections if the amount of Chlamydiaceae-DNA was too low (p1 IFU) for detection. Additionally, monocytes of the peripheral blood may not be infected in all patients but rather cells in the brain may be the reservoir, particularly microglia of the blood-brain barrier, which represent specialized monocytes (for a review, see Raivich and Banati 29 ). Furthermore, the heterogeneity of the schizophrenic disorder may reflect several pathogenic Abbreviations: CI, confidence interval; HLA, human lymphocyte antigen; NS, nonsignificant; OR, odds ratio. a All individuals are counted only once in one of the following groups: single-infected (C. psittaci, C. pneumoniae, C. trachomatis) or double-infected patients (C. pneumoniae þ C. trachomatis or C. psittaci þ C. pneumoniae). b The lower part summarizes all individuals which are single-or double-infected with C. psittaci (C. psittaci additional to C. psittaci þ C. pneumoniae) and those individuals single-or double-infected with any other Chlamydiaceae.
environmental factors as well as a variable genetic endowment, as proposed by several researchers. 30, 31 Prenatal, neonatal and adult infections leading to development of schizophrenia were repeatedly investigated, including viral, retroviral and bacterial pathogens. [1] [2] [3] 5, 6, [32] [33] [34] Several mechanisms of Chlamydophila infection may disturb brain function. Interestingly, the bloodbrain barrier seems to be disturbed in some stages of schizophrenia. 35 A disruption of the blood-brain barrier by C. pneumoniae, allowing intrusion of monocytes infected by other bacterial or viral pathogens, may explain several observations pointing to ongoing chronic infections: interleukin (IL)-2 levels were elevated in the cerebrospinal fluid (CSF) of patients. 36 Soluble IL-2 receptor levels were decreased in CSF of schizophrenic patients, but highly increased in serum in comparison with controls. 37 Furthermore, recurrence of psychosis in patients with elevated IL-2 levels was described. 38 IL-2 is produced by T helper 1 (Th-1) cells in an autocrine fashion, leading to expansion of Th-1 cells. Such preferential expansion of immune cells, induced for example by cytokine production of Chlamydiaceae-infected monocytes, 39 could favor production of distinct neurotrophins. Neurotrophins are responsible for prenatal neuronal differentiation and development as well as for postnatal neuronal plasticity. These considerations led to the 'neurotrophin hypothesis' of schizophrenic psychoses. 40 Recently, a different brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT-3) pattern was shown in schizophrenic patients compared to controls. 41 Both NT-3 and BDNF are known to influence neuronal plasticity. [42] [43] [44] We discovered previously that different human immune cell subpopulations, Th-1 and Th-2 cells, respectively, produced NT-3 and BDNF. 45 Production and uptake of both neurotrophins were dependent on Th-1-or Th-2-directed immune responses. 45, 46 Changes in the immune system may thereby affect neuronal processes. Adoptive immunotherapy was shown to have an effect on schizophrenic patients, 7, 8 presumably due to a change in cytokine/neurotrophin patterns. It has also been shown in an animal model that major histocompatibility complex (MHC) I expression is necessary for some forms of neuronal plasticity. 47 It can be speculated that aberrant MHC expression or alterations in cytokine/neurotrophin production in mothers with chlamydial infections could influence fetal neuronal development.
The route of C. psittaci infection is still open to discussion. In addition to infected birds and poultry, cats may serve as a natural serovar 48 because of the high rates of chlamydial infection in household cats and of asymptomatic carriage of C. psittaci in cats from breeding catteries. Usually, infection occurs through inhalation of dried feces or other secretions of infected birds; beak-to-mouth transmission is also possible. Person-to-person transmission has been suggested but not proven (for a review, see Peeling and Brunham 49 ). Because a very short time of exposure can lead to infection, interrogation of patients may not help to define sources of infection.
As carriers with HLA-A10 and infection by C. psittaci showed the highest risk of schizophrenia (OR = 50.0), these MHC class I molecules appear to be particularly unsuited to present chlamydial peptides and to elicit adequate immune responses. This genepathogen combination represents, to our knowledge, the highest risk factor found in the pathogenesis of schizophrenia. Our encouraging preliminary results with adoptive immunotherapy also improved schizophrenic patients without chlamydial infections. 8 Therefore, we believe that other microbial and genetic factors are also involved. Thus, complex interactions including polymorphic genes of the peptide processing and the HLA class I and II presentation system, as well as organisms, other than C. psittaci, may contribute to the development of schizophrenia. We hope that our results will inspire future search for other risk-associated immunogenic factors and other causative microbial agents in schizophrenia.
